Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Advaxis Announces Presentations at World Vaccine Congress 2012

Advaxis Inc.
Posted on: 10 Apr 12

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Dr. John Rothman, EVP of Science & Operations at Advaxis, and Dr. Robert Petit, VP of Clinical Operations at Advaxis, will present at the World Vaccine Congress 2012 at the Gaylord National Hotel and Convention Center in Washington, DC on April 10-12, 2012.

Dr. John Rothman will be presenting at the World Vaccine Partnering Congress on Tuesday, April 10 at 1:40pm EST. His oral presentation will address cancer vaccines, specifically ADXS-HPV, which is currently in Phase 2 trials for HPV-related diseases, and the Company’s preclinical constructs, ADXS-PSA and ADXS-HER2. Dr. Rothman will also present a poster on this work during the Congress.

Dr. Robert Petit will be presenting at the World Vaccine Trials Congress on Wednesday, April 11 at 2:05pm EST. His presentation, titled “Patient selection & successful outcomes,” will discuss patient selection factors in vaccine trials, special consideration of individual factors for trial sponsors, and examples of outcomes affected by patient factors. Dr. Petit will reference the Company’s Phase 2 clinical trials during his presentation.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (CRUK study). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Business Wire

Last updated on: 10/04/2012

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.